Global Immuno-Oncology Market Report 2018: Updated Forecasts to 2022 By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)] - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering.
The global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.
The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).
The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.
On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.
Trends & DevelopmentsLucrative Investment Trend Emergence of Targeted and Combination Therapies NSCLC & Melanoma Showing Greatest Contributions to the IO Market Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Dynamic
5. Global Immuno-Oncology Market Outlook 2022
6. Global Immuno-Oncology Market, by Product Class
7. Global Immuno-Oncology Market, By Major Indications
8. Global Immuno-Oncology Market, By Geography
9. Trends & Developments
10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry
11. Pipeline Analysis of Immuno-Oncology
12. Competitive Landscape
13. Key Players AnalysisAmgen Inc. AstraZeneca Plc Bristol-Myers Squibb Celgene Corporation Eli Lilly and Company F. Hoffmann-La Roche AG Johnson & Johnson Merck & Co., Inc. Novartis Pfizer Inc
For more information about this report visit https://www.researchandmarkets.com/research/cgtblj/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005077/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Leukemia Drugs,Lymphoma Drugs,Cancer Vaccines,Oncology
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 03:05 AM/DISC: 11/30/2018 03:05 AM